Canaccord lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $11 from $12 and keeps a Buy rating on the shares. The firm believes TriSalus has the foundation of a strong medical device business with a commercial footprint and catalysts to support it including new product launches and clinical data.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI: